PCBP4, poly(rC) binding protein 4, 57060

N. diseases: 147; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0730328
Disease: Central Serous Chorioretinopathy
Central Serous Chorioretinopathy 		0.010 AlteredExpression disease BEFREE <i>Conclusion:</i> CBP/β-catenin/FOXM1 transcriptional activity plays an important role in TNBC drug resistance and CSC phenotype. 30572639 2018
CUI: C3539878
Disease: Triple Negative Breast Neoplasms
Triple Negative Breast Neoplasms 		0.020 AlteredExpression disease BEFREE <i>Results:</i> The CBP/ß-catenin/FOXM1 transcriptional complex drives gene expression in TNBC and is associated with increased CSC numbers, drug resistance and poor survival outcome. 30572639 2018
CUI: C4722085
Disease: Malignant neoplasm of colon and/or rectum
Malignant neoplasm of colon and/or rectum 		0.010 Biomarker disease BEFREE 5-Fluorouracil targets histone acetyltransferases p300/CBP in the treatment of colorectal cancer. 28465257 2017
CUI: C0035934
Disease: Rubinstein-Taybi Syndrome
Rubinstein-Taybi Syndrome 		0.100 GeneticVariation disease BEFREE RSTS is associated with chromosomal rearrangements and mutations in the CREB-binding protein gene (CREBBP), also termed CBP, encoding the CREB-binding protein. 17220215 2007
CUI: C0035934
Disease: Rubinstein-Taybi Syndrome
Rubinstein-Taybi Syndrome 		0.100 AlteredExpression disease BEFREE Rubinstein-Taybi syndrome (RSTS) is a congenital neurodevelopmental disorder defined by postnatal growth deficiency, characteristic skeletal abnormalities and mental retardation and caused by mutations in the genes encoding for the transcriptional co-activators with intrinsic lysine acetyltransferase (KAT) activity CBP and p300. 21984751 2012
CUI: C0035934
Disease: Rubinstein-Taybi Syndrome
Rubinstein-Taybi Syndrome 		0.100 GeneticVariation disease BEFREE Rubinstein-Taybi syndrome (RSTS) is a rare neurodevelopmental disorder characterized by distinctive facial features, growth retardation, broad thumbs and toes and mild to severe intellectual disability, caused by heterozygous mutations in either CREBBP or EP300 genes, encoding the homologous CBP and p300 lysine-acetyltransferases and transcriptional coactivators. 29883886 2018
CUI: C0238288
Disease: Muscular Dystrophy, Facioscapulohumeral
Muscular Dystrophy, Facioscapulohumeral 		0.010 AlteredExpression disease BEFREE Facioscapulohumeral muscular dystrophy (FSHD) results from mutations causing overexpression of the transcription factor, DUX4, which interacts with the histone acetyltransferases, EP300 and CBP. 31535023 2019
CUI: C0035934
Disease: Rubinstein-Taybi Syndrome
Rubinstein-Taybi Syndrome 		0.100 Biomarker disease BEFREE CBP is the causative gene of Rubinstein-Taybi syndrome (RTS). 11331617 2001
CUI: C0032339
Disease: Rothmund-Thomson syndrome
Rothmund-Thomson syndrome 		0.080 Biomarker disease BEFREE CBP is the causative gene of Rubinstein-Taybi syndrome (RTS). 11331617 2001
CUI: C0035372
Disease: Rett Syndrome
Rett Syndrome 		0.080 Biomarker disease BEFREE CBP is the causative gene of Rubinstein-Taybi syndrome (RTS). 11331617 2001
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 AlteredExpression group BEFREE CBP is a multifunctional transcriptional cofactor with tumor suppressor activity. 12496368 2002
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.020 AlteredExpression phenotype BEFREE CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer's disease. 21149712 2010
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease 		0.030 AlteredExpression disease BEFREE CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer's disease. 21149712 2010
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE CBP may be a potential tumor suppressor and targeting the CBP gene may be an alternative strategy for the development of therapies for esophageal carcinoma. 25684946 2015
CUI: C0152018
Disease: Esophageal carcinoma
Esophageal carcinoma 		0.010 Biomarker disease BEFREE CBP may be a potential tumor suppressor and targeting the CBP gene may be an alternative strategy for the development of therapies for esophageal carcinoma. 25684946 2015
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.100 Biomarker group BEFREE PCBP4 is a novel molecular target for the therapy of head and neck cancers, especially cisplatin-resistant cancers. 26196957 2015
CUI: C0376545
Disease: Hematologic Neoplasms
Hematologic Neoplasms 		0.020 AlteredExpression group BEFREE CBP/p300 acetyltransferase activity in hematologic malignancies. 27380996 2016
CUI: C0011847
Disease: Diabetes
Diabetes 		0.010 AlteredExpression disease BEFREE CBP/p300-interacting transactivator with ED-rich tail 2 (CITED2), which was downregulated by insulin by up to 54%, is an important negative regulator of hypoxia-inducible factor (HIF) and impaired HIF signaling is a key mechanism underlying the impairment of angiogenesis in diabetes. 27561725 2016
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus 		0.010 AlteredExpression group BEFREE CBP/p300-interacting transactivator with ED-rich tail 2 (CITED2), which was downregulated by insulin by up to 54%, is an important negative regulator of hypoxia-inducible factor (HIF) and impaired HIF signaling is a key mechanism underlying the impairment of angiogenesis in diabetes. 27561725 2016
CUI: C0023449
Disease: Acute lymphocytic leukemia
Acute lymphocytic leukemia 		0.030 Biomarker disease BEFREE CBP Modulates Sensitivity to Dasatinib in Pre-BCR<sup>+</sup> Acute Lymphoblastic Leukemia. 30262461 2018
CUI: C1961102
Disease: Precursor Cell Lymphoblastic Leukemia Lymphoma
Precursor Cell Lymphoblastic Leukemia Lymphoma 		0.030 Biomarker disease BEFREE CBP Modulates Sensitivity to Dasatinib in Pre-BCR<sup>+</sup> Acute Lymphoblastic Leukemia. 30262461 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE CBP/p300 antagonises EGFR-Ras-Erk signalling and suppresses increased Ras-Erk signalling-induced tumour formation in mice. 30953353 2019
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis 		0.080 Biomarker disease BEFREE CBP is the first partner gene of MLL containing well defined structural and functional motifs that provide unique insights into the potential mechanisms by which these translocations contribute to leukemogenesis. 9238046 1997
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE CBP and p300 have properties of tumor suppressor proteins; their interaction with P/CAF is disrupted by the adenoviral E1A oncoprotein, and the genes encoding CBP and p300 are mutated in human cancer. 9288775 1997
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.100 Biomarker group BEFREE CBP and p300 have properties of tumor suppressor proteins; their interaction with P/CAF is disrupted by the adenoviral E1A oncoprotein, and the genes encoding CBP and p300 are mutated in human cancer. 9288775 1997